Emory University

Cancer Research Technology Limited

Imperial Innovations Limited

Imperial College Innovations Limited

Ip2ipo Innovations Limited

Imperial College of Science, Technology and Medicine

Matthew John Fuchter

James P Snyder

Simak Ali

Alexander Bondke

Charles Coombes

Brian Slafer

Anthony Barrett

Sebastian Kroll

Hugh J M Brady

Dennis C Liotta

Robert Albert Brown

Thota Ganesh

Anthony G M Barrett

Aiming Sun

Jin Liu

Ashutosh S Jogalekar

Alasdair Campbell

Gavin Whitlock

Amaia Uriz Huarte

Tomasz Kostrzewski

Sebastian H B Kroll

Matthew J Cook

Ying Yang

Joachim Caron

Nitipol Srimongkolpithak

Nadine Chapman-Rothe

Hugh Jm Brady

Robert Brown

James Patrick Snyder

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production.

Natural killer cells

The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.

4-ethynylpyridine derivatives useful as GCN2 inhibitors

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production.

Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use

Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use

This invention relates to quinazoline compounds of Formula (I) which are inhibitors of the histone lysine methyltransferase (HKMTase) EZH2, and to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of EZH2 provides a therapeutic or prophylactic effect. 

Quinazoline compounds and their use in therapy

The present invention relates to compositions capable of emitting circularly polarized electroluminescence comprising an electroluminescent polymer and a chiral dopant, processes for the synthesis of such compositions and light emitting devices incorporating such compositions.

Electroluminescent compositions

Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-&#x3b1;]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-&#x3b1;]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.

Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds

Growing community of inventors

East Sussex, United Kingdom

Matthew John Fuchter